X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (213888) 213888
Newspaper Article (1693) 1693
Book Chapter (702) 702
Newsletter (483) 483
Book / eBook (128) 128
Magazine Article (62) 62
Web Resource (43) 43
Dissertation (41) 41
Transcript (23) 23
Conference Proceeding (22) 22
Book Review (18) 18
Reference (14) 14
Trade Publication Article (11) 11
Government Document (5) 5
Publication (5) 5
Streaming Video (4) 4
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (126014) 126014
animals (91154) 91154
proteins (65978) 65978
kinases (47074) 47074
oncology (46803) 46803
mice (45336) 45336
cancer (45266) 45266
male (45240) 45240
apoptosis (44647) 44647
female (40166) 40166
cell biology (35282) 35282
signal transduction (35013) 35013
gene expression (34904) 34904
expression (34011) 34011
research (30530) 30530
phosphorylation (28801) 28801
cell line, tumor (27034) 27034
biochemistry & molecular biology (26437) 26437
activation (25858) 25858
research article (24511) 24511
multidisciplinary sciences (23363) 23363
medicine (23326) 23326
analysis (23111) 23111
tumors (22773) 22773
health aspects (22335) 22335
inflammation (21175) 21175
rodents (20458) 20458
mutation (20255) 20255
genetic aspects (19485) 19485
rats (19318) 19318
pharmacology & pharmacy (19292) 19292
science (18389) 18389
care and treatment (17893) 17893
middle aged (17839) 17839
biology (17782) 17782
physiological aspects (17617) 17617
neurosciences (16624) 16624
inhibition (16546) 16546
metastasis (16217) 16217
cell cycle (15883) 15883
cell proliferation (15714) 15714
signal transduction - drug effects (15610) 15610
oxidative stress (15254) 15254
cells (14783) 14783
medicine, research & experimental (14604) 14604
chemotherapy (14484) 14484
antineoplastic agents - therapeutic use (14357) 14357
adult (14224) 14224
aged (14038) 14038
protein kinase inhibitors - therapeutic use (13997) 13997
apoptosis - drug effects (13986) 13986
studies (13942) 13942
cells, cultured (13368) 13368
immunology (13306) 13306
cytokines (12915) 12915
cancer therapies (12842) 12842
review (12836) 12836
development and progression (12630) 12630
breast cancer (12513) 12513
protein (12462) 12462
genes (12379) 12379
disease models, animal (12345) 12345
metabolism (11853) 11853
cell growth (11804) 11804
gene-expression (11595) 11595
physiology (11532) 11532
antineoplastic agents - pharmacology (11393) 11393
growth (11351) 11351
stem cells (11290) 11290
in-vitro (11081) 11081
medical research (10843) 10843
mice, inbred c57bl (10796) 10796
enzymes (10767) 10767
biochemistry (10646) 10646
cell proliferation - drug effects (10585) 10585
deoxyribonucleic acid--dna (9855) 9855
nf-kappa-b (9755) 9755
cell line (9737) 9737
angiogenesis (9725) 9725
hematology (9587) 9587
prognosis (9506) 9506
immunohistochemistry (9455) 9455
proliferation (9345) 9345
survival (9265) 9265
disease (9255) 9255
signaling (9251) 9251
transcription factors (9135) 9135
medical prognosis (9066) 9066
in-vivo (8896) 8896
protein kinase inhibitors - pharmacology (8868) 8868
pathology (8678) 8678
therapy (8581) 8581
medicine & public health (8519) 8519
pathogenesis (8497) 8497
cell death (8267) 8267
treatment outcome (8243) 8243
patients (8153) 8153
pathway (8147) 8147
ligands (8122) 8122
transcription (8101) 8101
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (30) 30
Gerstein Science - Stacks (26) 26
Collection Dvlpm't (Acquisitions) - Vendor file (13) 13
UofT at Mississauga - Stacks (7) 7
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (3) 3
Chemistry (A D Allen) - Stacks (2) 2
UofT at Scarborough - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Gerstein Science - Not Returned (1) 1
St. Michael's Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (216102) 216102
Japanese (591) 591
French (367) 367
German (341) 341
Chinese (314) 314
Spanish (99) 99
Norwegian (74) 74
Portuguese (64) 64
Hungarian (41) 41
Dutch (37) 37
Italian (35) 35
Czech (30) 30
Russian (28) 28
Polish (27) 27
Danish (14) 14
Turkish (12) 12
Swedish (10) 10
Croatian (7) 7
Korean (6) 6
Finnish (4) 4
Ukrainian (4) 4
Hebrew (2) 2
Romanian (2) 2
Slovenian (2) 2
Arabic (1) 1
Bulgarian (1) 1
Nauru (1) 1
Serbian (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2012, Methods in molecular biology, ISBN 1617793361, Volume 795., xi, 256
Book
Cellular and molecular life sciences : CMLS, ISSN 1420-9071, 2008, Volume 66, Issue 7, pp. 1163 - 1177
Journal Article
The Journal of clinical investigation, ISSN 0021-9738, 2009, Volume 119, Issue 5, pp. 1109 - 1123
Imatinib mesylate (IM), a potent inhibitor of the BCR/ABL tyrosine kinase, has become standard first-line therapy for patients with chronic myeloid leukemia (CML... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, RESEARCH & EXPERIMENTAL | MALIGNANT GLIOMA-CELLS | BLAST CRISIS | CLINICAL RESISTANCE | BCR-ABL MUTATIONS | ENDOPLASMIC-RETICULUM | CYTOCHROME-C RELEASE | CASPASE ACTIVATION | IMATINIB RESISTANCE | CHRONIC MYELOID-LEUKEMIA | Transcription Factor CHOP - genetics | Neoplastic Stem Cells - cytology | Gene Expression - drug effects | Calcium - metabolism | Gene Expression - genetics | Microtubule-Associated Proteins - metabolism | Neoplastic Stem Cells - drug effects | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Endoplasmic Reticulum - metabolism | Antineoplastic Agents - therapeutic use | Autophagy - physiology | Thiazoles - therapeutic use | Autophagy - drug effects | Chloroquine - pharmacology | Neoplastic Stem Cells - metabolism | RNA Interference | Endoplasmic Reticulum - drug effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Macrolides - pharmacology | Antineoplastic Agents - pharmacology | Cell Death - drug effects | Dasatinib | Chloroquine - therapeutic use | Piperazines - therapeutic use | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Mice, Inbred C3H | Xenograft Model Antitumor Assays | Fusion Proteins, bcr-abl - genetics | Animals | Cell Death - physiology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Mice | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Benzamides | Macrolides - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors | Causes of | Physiological aspects | Genetic aspects | Chronic myeloid leukemia | Research | Drug therapy | Phagocytosis
Journal Article
The Journal of clinical investigation, ISSN 0021-9738, 2015, Volume 125, Issue 5, pp. 1780 - 1789
Kinase inhibitors have played an increasingly prominent role in the treatment of cancer and other diseases... 
MEDICINE, RESEARCH & EXPERIMENTAL | ONCOGENIC ACTIVATION | PROTEIN-KINASE | TUMOR-INFILTRATING MACROPHAGES | ADAPTIVE RESISTANCE | ACQUIRED-RESISTANCE | CLINICAL RESISTANCE | DIACYLGLYCEROL KINASES | RECEPTOR TYROSINE KINASE | IMATINIB MESYLATE | ANTITUMOR EFFICACY | Immunotherapy - methods | Apoptosis - drug effects | Humans | Substrate Specificity | Drug Resistance, Neoplasm | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Neoplasms - genetics | Protein Processing, Post-Translational - drug effects | Drug Design | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Phosphorylation - drug effects | Neoplasm Proteins - genetics | Molecular Targeted Therapy - methods | Neoplasms - enzymology | Gene Fusion | Enzyme Activation - drug effects | Neoplasms - drug therapy | Drug Synergism | Point Mutation | Gene Amplification | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Oncogene Proteins, Fusion - antagonists & inhibitors | Signal Transduction - physiology | Protein Kinase Inhibitors - pharmacology | Apoptosis - physiology | Enzyme inhibitors | Physiological aspects | Research | Drug therapy | Phosphotransferases | Health aspects | Cancer | Proteins | Phosphorylation | Gene amplification | Biology | Regulation | Genomes | Mutation | Metastasis | Kinases | Phosphatase | Tumors | Review
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2012, Volume 30, Issue 5, pp. 482 - 487
Journal Article
Current medicinal chemistry, ISSN 0929-8673, 2017, Volume 24, Issue 16, pp. 1 - 16
... the most clinically practiced therapeutic approaches, the modulation of multiple proteins by a single drug, in accordance... 
Tumor microenvironment | Fda-Approved drugs | Multitargeted drugs | Anticancer agents | Polypharmacology | Tyrosine kinase receptors | Oncogene addiction | CHRONIC MYELOGENOUS LEUKEMIA | CHEMISTRY, MEDICINAL | GROWTH-FACTOR-RECEPTOR | TARGETED-THERAPY | TYROSINE KINASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | REGORAFENIB BAY 73-4506 | BCR-ABL INHIBITOR | anticancer agents | FDA-approved drugs | CELL LUNG-CANCER | tyrosine kinase receptors | oncogene addiction | polypharmacology | PHILADELPHIA-CHROMOSOME | COLORECTAL-CANCER | PHARMACOLOGY & PHARMACY | tumor microenvironment | GASTROINTESTINAL STROMAL TUMORS | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Pyrazoles - therapeutic use | Pyridines - chemistry | Humans | Anilides - chemistry | Imidazoles - chemistry | Imatinib Mesylate - therapeutic use | Protein Kinase Inhibitors - chemistry | Pyrazoles - chemistry | Niacinamide - chemistry | Phenylurea Compounds - chemistry | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Imidazoles - therapeutic use | Pyrroles - therapeutic use | Quinazolines - chemistry | Pyridazines - therapeutic use | Pyridines - therapeutic use | Piperidines - chemistry | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Receptor Protein-Tyrosine Kinases - metabolism | Imatinib Mesylate - chemistry | Neoplasms - drug therapy | Pyridazines - chemistry | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Pyrroles - chemistry | Indoles - therapeutic use | Neoplasms - pathology | Indoles - chemistry | Tyrosine | Cell proliferation | Drugs | Medical research | Phenotypes | Clinical trials | Kinases | Proteins | Inhibitors | Modulation | Protein-tyrosine kinase | Deoxyribonucleic acid--DNA | Cancer
Journal Article
Journal of thoracic oncology, ISSN 1556-0864, 2012, Volume 7, Issue 12, pp. 1807 - 1814
Many patients with oncogene-driven non–small-cell lung cancer (NSCLC) treated with tyrosine kinase inhibitors experience limited sites of disease progression... 
anaplastic lymphoma kinase gene arrangement non–small-cell lung cancer | EGFR-mutant non–small-cell lung cancer | Radiation therapy | Oligoprogressive disease | anaplastic lymphoma kinase gene arrangement non-small-cell lung cancer | EGFR-mutant non-small-cell lung cancer | PHASE-I/II TRIAL | ACQUIRED-RESISTANCE | BODY RADIATION-THERAPY | DOSE WEEKLY ERLOTINIB | BREAST-CANCER | LIVER METASTASES | SYNCHRONOUS BRAIN METASTASES | STEREOTACTIC RADIOSURGERY | ONCOLOGY | LEPTOMENINGEAL METASTASES | RESPIRATORY SYSTEM | RECURRENT MALIGNANT GLIOMAS | Erlotinib Hydrochloride | Receptor, Epidermal Growth Factor - genetics | Pyrazoles - therapeutic use | Prognosis | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Catheter Ablation | Lung Neoplasms - pathology | Male | Young Adult | Brain Neoplasms - secondary | Aged, 80 and over | Adult | Female | Retrospective Studies | Brain Neoplasms - mortality | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Survival Rate | Combined Modality Therapy | Lung Neoplasms - therapy | Mutation - genetics | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Carcinoma, Non-Small-Cell Lung - therapy | Receptor Protein-Tyrosine Kinases - genetics | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Gene Rearrangement | Brain Neoplasms - therapy | Aged | Neoplasm Staging
Journal Article
The Journal of clinical investigation, ISSN 0021-9738, 12/2011, Volume 121, Issue 12, pp. 4700 - 4711
Advanced human thyroid cancers, particularly those that are refractory to treatment with radioiodine (RAI), have a high prevalence of BRAF (v-raf murine... 
MEDICINE, RESEARCH & EXPERIMENTAL | GROWTH-INHIBITION | BRAF(V600E) MUTATION | CARCINOMA CELLS | GENE | RAS | ANTISENSE RNA | KINASE | SENSITIVITY | PROLIFERATION | EXPRESSION | MAP Kinase Signaling System - physiology | Proto-Oncogene Proteins B-raf - physiology | Apoptosis - drug effects | Humans | Antineoplastic Agents - therapeutic use | Mutation, Missense | Indoles - administration & dosage | Benzamides - administration & dosage | Neoplasm Proteins - genetics | MAP Kinase Kinase 1 - antagonists & inhibitors | Benzamides - toxicity | Diphenylamine - therapeutic use | Carcinoma, Papillary - drug therapy | Mice, Transgenic | Diphenylamine - toxicity | Sulfonamides - pharmacology | Antineoplastic Combined Chemotherapy Protocols - toxicity | Protein Kinase Inhibitors - administration & dosage | Indoles - therapeutic use | Mice | DNA Damage | Thyroid Gland - metabolism | Sulfonamides - administration & dosage | Thyroid Neoplasms - metabolism | Carcinoma, Papillary - genetics | Diphenylamine - pharmacology | Neoplasm Proteins - physiology | Carcinoma, Papillary - metabolism | Diphenylamine - analogs & derivatives | Benzamides - therapeutic use | Indoles - pharmacology | Benzamides - pharmacology | Diphenylamine - administration & dosage | Genes, Synthetic - drug effects | Indoles - toxicity | Enzyme Activation - drug effects | Iodine Radioisotopes - pharmacokinetics | Carcinoma, Papillary - pathology | Point Mutation | Thyroid Neoplasms - genetics | Animals | MAP Kinase Signaling System - drug effects | Sulfonamides - therapeutic use | Thyroid Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Protein Kinase Inhibitors - toxicity | Sulfonamides - toxicity | Protein Kinase Inhibitors - pharmacology | Doxorubicin - pharmacology | Drug Screening Assays, Antitumor | Thyroid Neoplasms - pathology | Care and treatment | Thyroid cancer | Cancer cells | Genetic aspects | Diagnosis | Properties | Isotopes | Health aspects | Mitogen-activated protein kinases | Iodine
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 370, Issue 24, pp. 2286 - 2294
Journal Article
Chemical Biology & Drug Design, ISSN 1747-0277, 01/2011, Volume 77, Issue 1, pp. 1 - 11
The BCR‐ABL inhibitor imatinib has revolutionized the treatment of chronic myeloid leukemia... 
kinase | ponatinib | AP24534 | drug discovery | X‐ray crystallography | structure‐based drug design | X-ray crystallography | Structure-based drug design | Drug discovery | Ponatinib | Kinase | structure-based drug design | C-ABL | CRYSTAL-STRUCTURE | BIOCHEMISTRY & MOLECULAR BIOLOGY | BMS-354825 | DOMAIN MUTATIONS | CANCER | CHRONIC MYELOID-LEUKEMIA | STRATEGIES | THERAPY | IMATINIB | T315I MUTANT | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Crystallography, X-Ray | Piperazines - chemistry | Structure-Activity Relationship | Pyridazines - pharmacology | Pyridazines - chemical synthesis | Pyrimidines - chemistry | Protein Kinase Inhibitors - chemistry | Protein Binding - drug effects | Imidazoles - chemical synthesis | Imidazoles - therapeutic use | Pyridazines - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Imidazoles - pharmacology | Piperazines - therapeutic use | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Drug Resistance, Neoplasm - genetics | Fusion Proteins, bcr-abl - genetics | Animals | Mutation - drug effects | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Mice | Protein Kinase Inhibitors - pharmacology | Benzamides | Fluoroimmunoassay | Fusion Proteins, bcr-abl - metabolism | Drug Resistance, Neoplasm - drug effects | Drug resistance | Analysis | Leukemia | STRUCTURE-ACTIVITY RELATIONSHIPS | MUTANTS | BASIC BIOLOGICAL SCIENCES | ENZYME INHIBITORS | TYROSINE | GENE MUTATIONS | PHOSPHOTRANSFERASES | MYELOID LEUKEMIA | MUTATIONS | ANTINEOPLASTIC DRUGS | 60 APPLIED LIFE SCIENCES | RESIDUES
Journal Article